These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 25931141)

  • 1. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study).
    Rosenstock J; Hollander P; Bhargava A; Ilag LL; Pollom RK; Zielonka JS; Huster WJ; Prince MJ
    Diabetes Obes Metab; 2015 Aug; 17(8):734-41. PubMed ID: 25931141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study.
    Blevins TC; Dahl D; Rosenstock J; Ilag LL; Huster WJ; Zielonka JS; Pollom RK; Prince MJ
    Diabetes Obes Metab; 2015 Aug; 17(8):726-33. PubMed ID: 25974640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial.
    Feng W; Chen W; Jiang S; Du L; Zhu D
    Diabetes Obes Metab; 2021 Aug; 23(8):1786-1794. PubMed ID: 33783964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine.
    Hadjiyianni I; Dahl D; Lacaya LB; Pollom RK; Chang CL; Ilag LL
    Diabetes Obes Metab; 2016 Apr; 18(4):425-9. PubMed ID: 26749289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial.
    Yan X; Jiang S; Lou Y; Zhou Z
    Diabetes Obes Metab; 2021 Oct; 23(10):2226-2233. PubMed ID: 34121308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lilly Insulin Glargine Versus Lantus
    Mohan V; Ahn KJ; Cho YM; Sahay RK; Huang CN; Kalra S; Chadha M; Bhattacharya I; Kim SY; Spaepen E
    Clin Drug Investig; 2019 Aug; 39(8):745-756. PubMed ID: 31119716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.
    Ilag LL; Deeg MA; Costigan T; Hollander P; Blevins TC; Edelman SV; Konrad RJ; Ortmann RA; Pollom RK; Huster WJ; Zielonka JS; Prince MJ
    Diabetes Obes Metab; 2016 Feb; 18(2):159-68. PubMed ID: 26434665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lilly Insulin Glargine Versus Lantus
    Pollom RK; Ilag LL; Lacaya LB; Morwick TM; Ortiz Carrasquillo R
    Diabetes Ther; 2019 Feb; 10(1):189-203. PubMed ID: 30604091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus
    Yan X; Feng C; Lou Y; Zhou Z
    Diabetes Ther; 2022 Jun; 13(6):1161-1174. PubMed ID: 35471721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
    Pan C; Gross JL; Yang W; Lv X; Sun L; Hansen CT; Xu H; Wagner R
    Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus.
    Wang W; Song X; Lou Y; Du L; Zhu D; Zhou Z
    Diabetes Obes Metab; 2022 Jun; 24(6):1094-1104. PubMed ID: 35187770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.
    Linnebjerg H; Lam EC; Zhang X; Seger ME; Coutant D; Chua L; Kapitza C; Heise T
    Diabetes Obes Metab; 2017 Jan; 19(1):33-39. PubMed ID: 27484286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial.
    Halberg IB; Lyby K; Wassermann K; Heise T; Zijlstra E; Plum-Mörschel L
    Lancet Diabetes Endocrinol; 2019 Mar; 7(3):179-188. PubMed ID: 30679095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.
    Hollander PA; Carofano WL; Lam RLH; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rendell MS; Home PD; Gallwitz B; Rosenstock J
    Diabetes Obes Metab; 2018 Sep; 20(9):2229-2237. PubMed ID: 29761615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
    Aroda VR; Rosenstock J; Wysham C; Unger J; Bellido D; González-Gálvez G; Takami A; Guo H; Niemoeller E; Souhami E; Bergenstal RM;
    Diabetes Care; 2016 Nov; 39(11):1972-1980. PubMed ID: 27650977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
    Rosenstock J; Aronson R; Grunberger G; Hanefeld M; Piatti P; Serusclat P; Cheng X; Zhou T; Niemoeller E; Souhami E; Davies M;
    Diabetes Care; 2016 Nov; 39(11):2026-2035. PubMed ID: 27527848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
    Yang W; Dong X; Li Q; Cheng Z; Yuan G; Liu M; Xiao J; Gu S; Niemoeller E; Chen L; Ping L; Souhami E;
    Diabetes Obes Metab; 2022 Aug; 24(8):1522-1533. PubMed ID: 35441412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial].
    Mu YM; Guo LX; Li L; Li YM; Xu XJ; Li QM; Xu MT; Zhu LY; Yuan GY; Liu Y; Xu C; Wang ZJ; Shen FX; Luo Y; Liu JY; Li QF; Wang WH; Lai XY; Xu HF; Pan CY
    Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):660-666. PubMed ID: 28870034
    [No Abstract]   [Full Text] [Related]  

  • 19. Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial.
    Yuan X; Guo X; Zhang J; Dong X; Lu Y; Pang W; Gu S; Niemoeller E; Ping L; Nian G; Souhami E;
    Diabetes Obes Metab; 2022 Nov; 24(11):2182-2191. PubMed ID: 35762489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
    Christofides EA; Puente O; Norwood P; Denham D; Maheshwari H; Lillestol M; Hart T; Nakhle S; Chadha A; Fitz-Patrick D; Sugimoto D; Soufer J; Young D; Warren M; Huffman D; Reed J; Bays H; Arora S; Rizzardi B; Tidman R; Rendell M; Johnson KA
    Diabetes Obes Metab; 2024 Jun; 26(6):2412-2421. PubMed ID: 38558508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.